Is A GLP-1 Right For Me? Who Weight Loss Medications Fit And Who They Don't
Semaglutide and tirzepatide get talked about as if anyone who wants to drop a few pounds should be on one. That isn't who they were studied in or approved for. Here's who they fit, who they don't, and what a provider weighs first.
Who The Approved Labels Cover
The FDA-approved weight management versions, Wegovy (semaglutide) and Zepbound (tirzepatide), are labeled for adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Both are meant to be used alongside a reduced-calorie diet and more physical activity. The main trials behind them, STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide, enrolled people who met those same BMI criteria. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity.
What That Means For Compounded Versions
The semaglutide and tirzepatide in Urania's catalog are compounded. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness, so they have no approved label of their own. The approved labels are still the clearest picture of who these medicines were tested in, and their warnings are about the active ingredient. Our guide to compounded vs. brand-name GLP-1s explains the difference.
Who Generally Shouldn't Take One
Both labels carry a boxed warning about thyroid C-cell tumors seen in rodent studies. Neither medicine is used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or by anyone who has had a serious allergic reaction to it. They aren't used during pregnancy, and tirzepatide can make birth control pills less reliable; our guide to GLP-1s, birth control, and pregnancy covers what the labels say. They also shouldn't be combined with another GLP-1 medicine.
History To Bring Up With Your Provider
Some history doesn't rule you out but changes how closely you're watched. The labels warn about pancreatitis, gallbladder problems, and kidney injury from dehydration, so mention any past pancreatitis, gallstones, or kidney disease. If you take insulin or a sulfonylurea for diabetes, the risk of low blood sugar goes up. Both labels also ask that you watch for depression or thoughts of suicide. Recent labs give a provider a useful baseline; our guide to A1c, glucose, and insulin tests explains the blood sugar side.
It's Usually A Long-Term Plan
These medicines work while you take them. In the STEP 4 trial (JAMA, 2021), people who switched from semaglutide to placebo after 20 weeks regained weight over the following year, while those who stayed on it continued to lose. The SURMOUNT-4 trial (JAMA, 2024) found the same pattern with tirzepatide. That's worth knowing before you start, for your expectations and your budget.
Where To Start
Every Urania weight loss program starts with an intake that a licensed provider reviews. They look at your weight history, health conditions, medications, and pregnancy plans, and decide whether a GLP-1 fits you at all, and if so, which one and at what dose.
This guide explains general information and is not medical advice. It doesn't replace a licensed provider reviewing your own history.